



Negative Weak Positive

Positive

Total=73



Supplementary Fig. 1: Anti-Nuclear Antibody (ANA) staining in University of Pennsylvania **COVID-19 patient cohort.** a. IgG ANA indirect immunofluorescence results at a screening titer of 1:80, with positives confirmed at 1:160. Pie chart shows patient numbers (n=73 total), color coded by strength of staining and pattern. b. Analysis of ANA data in paired samples obtained on 21 patients showing the number of patients whose ANAs change over time. **d.** Images of positive ANAs from individual subjects, showing diffuse (left), nucleolar (middle) and speckled (right) staining patterns. Of note, UP01 was also weakly positive for dsDNA antibodies.

Negative with Cytoplasmic





Supplementary Fig. 2: lgG ELISAs Of virus and autoantigen-binding. Binding of IgG antibodies to SARS-CoVreceptor binding domain 2 (RBD), nucleocapsid, and autoantigens (double stranded DNA (dsDNA), myeloperoxidase (MPO) and proteinase 3 (PR3)). Each symbol represents a patient (N=73). For subjects in which there were two or more time points, the D7 time point was chosen except for subject UP68, in whom the D14 time point was chosen. UP01 had a weakly positive dsDNA result. UP43 was positive for PR3.

Supplementary Fig. 3: Heatmap of MFI corresponding to Figure 1.



60,000

80,000

40,000

20,000

E 0





Supplementary Fig. 4: Validation in Kaiser Permanente cohort. Standard deviation heatmap depicting serum IgG antibodies discovered using a first generation 26-plex bead-based protein array containing the indicated autoantigens (y-axis). Autoantigens are grouped based on disease (scleroderma, SLE/Sjögren's, primary biliary cirrhosis (PBC)/thyroid, nucleosomes, and antigens associated with tissue inflammation. COVID-19 patients from Kaiser Permanente (left panel, n=48). HC (n=10, middle panel), and 7 prototype autoimmune disorders (right panel) are shown. Colors indicate autoantibodies whose MFI measurements are >5 SD (red), <5 or >3 SD (pink) or <3 SD (black) above the average MFI for HC. MFIs <5,000 were excluded.



Supplementary Fig. 5: Evolution of IgG autoantibody development over time

in hospitalized COVID-19 patients. a. Heatmap using the same 53-plex beadbased protein array presented in Figure 1, containing the indicated autoantigens (x-axis). Autoantigens are grouped based on disease (scleroderma, myositis and overlap syndromes such as MCTD, SLE/Sjögren's, gastrointestinal and endocrine disorders), DNA-associated antigens, and antigens associated with tissue inflammation or stress responses. COVID-19 patients (top panel, n=98) longitudinal COVID-19 samples, including 92 paired samples from 46 subjects and two subjects who had three available timepoints each, subject UP70 and UP71). HC (n=16, middle panel), and 8 prototype autoimmune disorders (bottom panel) are shown. b. Heatmap using a 41-plex array of cytokines, chemokines, growth factors, and receptors. The same samples in Panel A were also analyzed for ACA. Cytokines are grouped on the x-axis by category (interferons, interleukins, and other cytokines/growth factors/receptors). Prototype samples from patients with immunodeficiency disorders include three patients with APS1, one patient with PAP, and three patients with AMI. Colors correspond to the MFI values shown at far right.

Supplementary Fig. 6: Standard deviation heatmap of MFI corresponding to Figure 3.

Supplementary Fig. 7: Number of antibodies in 21 subjects with paired D0 and D7 time point data, stratified by reactivity category. a. Heatmap of individual subjects. Rows denote subjects and time points in days (day 0, D0) and day 7, D7). Columns denote Autoantibodies (AutoAb) and Anti-Cytokine Antibodies (ACA). Antibodies are above 5 standard deviations compared to pooled healthy controls (5 SD) or between 3 and 5 standard deviations (3 SD). White cells indicate 0 antibodies. b. Antibody counts at D0 and D7 stratified by antibody category. Autoantibody (AutoAb, blue) and anti-cytokine antibody (ACA, yellow) counts are shown for the same 21 subjects at Day 0, (left) and Day 7 (right). Counts were based on antibodies that were present at levels between 3 and 5 SD above the average MFI for healthy control samples. c. Antibodies per subject shown for different antibody level cut-offs. 5 SD = > 5 SDabove the average MFI for the HC group; 3 SD = >3 and <5 SD above the average MFI for HC; In SUM, the 5 and 3 SD data were separately added for each individual. This category represents all antibodies detected at 3 SD or higher. AutoAb = autoantibodies; ACA = anti-cytokine antibodies. Horizontal red lines indicate medians. Each symbol represents a subject. P values are computed using the Wilcoxon paired rank sum test. Only D7 AutoAb vs. D7 ACA were significant (p<0.05) for the 3 SD and SUM antibody levels.

C

RBD

Index Value

d

2.07

Supplementary Fig. 8: Comparison between ELISA and beadbased assays. a and b. Correlation analysis between ELISA and multiplex bead data. All samples (including multiple time points from individual subjects) were included in the correlation analysis (N=57 samples from 35 individuals). Each symbol represents a sample with the mean fluorescence intensity (MFI) vs. the optical density (OD). Spearman correlations were computed with two-tailed p-values. c and d. Two representative line plots for 21 patients with paired samples at D0 and D7. IgG antibodies increased over time for RBD (p=0.042, Wilcoxon rank sum test) but did not change over time for Nucleocapsid (p=0.73, NS, Wilcoxon rank sum test).

triggered autoantibodies, corresponding to Figure 5. Error bars represent one standard deviation of the MFI for sample replicates.

Autoantigens

UP52 D0 (Blue) vs. D7 (Orange)

